B
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Bahaa Mustafa's research focuses on developing novel therapeutic strategies for cancer immunotherapy, with a particular emphasis on targeting immune checkpoints. His work has involved the discovery and development of peptide-based inhibitors and domain antibodies that target Programmed Death-Ligand 1 (PD-L1), a key regulator of immune responses in the tumor microenvironment. Mustafa has also investigated the use of oncolytic viruses in combination with immune checkpoint blockade to enhance anti-tumor immunity in models of hepatocellular carcinoma and pancreatic cancer.
His research extends to the development of peptide-based inhibitors targeting ACE2 to inhibit SARS-CoV-2 infectivity, demonstrating a broader interest in peptide therapeutics. Mustafa has a publication record of 16 articles, with an h-index of 4 and 92 citations. He collaborates with researchers at the University of Arkansas for Medical Sciences and Arkansas State University, including Mulu Z. Tesfay, Martin J. Cannon, Alexei G. Basnakian, and Khandoker Usran Ferdous.
Metrics
- h-index: 4
- Publications: 16
- Citations: 96
Selected Publications
-
Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models (2025)
-
Abstract B022: Reprogramming Apoptotic Resistance in PDAC Through Synthetic Oncolytic Immunotherapy (2025)
-
Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response (2025)
-
Abstract 2155: Phage display discovery of Trop-2 peptide for targeted liposomal chemo-immunotherapy in lung cancer (2025)
-
Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models (2025)
-
Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma (2025)
-
Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade (2024)
-
Anti-CD47 Peptide Combined with Oncolytic Vesiculovirus-Driven Intratumoral Immunotherapy for Colorectal Cancer (2024)
-
Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer (2024)
Collaboration Network
Top Collaborators
Mulu Z. Tesfay
University of Arkansas for Medical Sciences
8 shared publications
In database
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma
- Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models
- Abstract 2155: Phage display discovery of Trop-2 peptide for targeted liposomal chemo-immunotherapy in lung cancer
Showing 5 of 8 shared publications
Aleksandra Cios
Winthrop Rockefeller Foundation (US)
8 shared publications
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma
- Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models
- Abstract 2155: Phage display discovery of Trop-2 peptide for targeted liposomal chemo-immunotherapy in lung cancer
Showing 5 of 8 shared publications
Khandoker Usran Ferdous
University of Arkansas for Medical Sciences
7 shared publications
In database
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma
- Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models
- Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response
Showing 5 of 7 shared publications
Kun Cheng
University of Missouri–Kansas City (US)
6 shared publications
- Discovery of Cyclic Peptide Inhibitors Targeting PD-L1 for Cancer Immunotherapy
- Discovery of Small Anti‐ACE2 Peptides to Inhibit SARS‐CoV‐2 Infectivity
- Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy
- Development of a peptide-based tumor-activated checkpoint inhibitor for cancer immunotherapy
- Discovery of Small Anti‐ACE2 Peptides to Inhibit SARS‐CoV‐2 Infectivity (Adv. Therap. 7/2021)
Showing 5 of 6 shared publications
Omeed Moaven
Louisiana State University Health Sciences Center New Orleans (US)
6 shared publications
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma
- Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response
- Abstract B022: Reprogramming Apoptotic Resistance in PDAC Through Synthetic Oncolytic Immunotherapy
Showing 5 of 6 shared publications
Steven R. Post
University of Arkansas for Medical Sciences
6 shared publications
In database
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma
- Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models
- Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response
Showing 5 of 6 shared publications
Martin J. Cannon
University of Arkansas for Medical Sciences
6 shared publications
In database
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma
- Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models
- Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response
- Abstract B022: Reprogramming Apoptotic Resistance in PDAC Through Synthetic Oncolytic Immunotherapy
Showing 5 of 6 shared publications
Umar‐Farouk Mamani
University of Missouri–Kansas City (US)
5 shared publications
- Discovery of Cyclic Peptide Inhibitors Targeting PD-L1 for Cancer Immunotherapy
- Discovery of Small Anti‐ACE2 Peptides to Inhibit SARS‐CoV‐2 Infectivity
- Development of a peptide-based tumor-activated checkpoint inhibitor for cancer immunotherapy
- Discovery of Small Anti‐ACE2 Peptides to Inhibit SARS‐CoV‐2 Infectivity (Adv. Therap. 7/2021)
- Discovery of Anti‐CD47 Peptides as Innate Immune Checkpoint Inhibitors
John Fetse
University of Missouri–Kansas City (US)
5 shared publications
- Discovery of Cyclic Peptide Inhibitors Targeting PD-L1 for Cancer Immunotherapy
- Discovery of Small Anti‐ACE2 Peptides to Inhibit SARS‐CoV‐2 Infectivity
- Development of a peptide-based tumor-activated checkpoint inhibitor for cancer immunotherapy
- Discovery of Small Anti‐ACE2 Peptides to Inhibit SARS‐CoV‐2 Infectivity (Adv. Therap. 7/2021)
- Discovery of Anti‐CD47 Peptides as Innate Immune Checkpoint Inhibitors
Randal S. Shelton
University of Arkansas for Medical Sciences
5 shared publications
In database
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models
- Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
Camila Simões
University of Arkansas for Medical Sciences
5 shared publications
In database
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade
- Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models
- Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
Alexei G. Basnakian
University of Arkansas for Medical Sciences
5 shared publications
In database
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma
- Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models
- Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response
- Abstract B022: Reprogramming Apoptotic Resistance in PDAC Through Synthetic Oncolytic Immunotherapy
Pratik Adhikary
University of Missouri–Kansas City (US)
4 shared publications
- Discovery of Cyclic Peptide Inhibitors Targeting PD-L1 for Cancer Immunotherapy
- Discovery of Small Anti‐ACE2 Peptides to Inhibit SARS‐CoV‐2 Infectivity
- Discovery of Small Anti‐ACE2 Peptides to Inhibit SARS‐CoV‐2 Infectivity (Adv. Therap. 7/2021)
- Discovery of Anti‐CD47 Peptides as Innate Immune Checkpoint Inhibitors
Chien‐Yu Lin
University of Missouri–Kansas City (US)
4 shared publications
- Discovery of Small Anti‐ACE2 Peptides to Inhibit SARS‐CoV‐2 Infectivity
- Development of a peptide-based tumor-activated checkpoint inhibitor for cancer immunotherapy
- Discovery of Small Anti‐ACE2 Peptides to Inhibit SARS‐CoV‐2 Infectivity (Adv. Therap. 7/2021)
- Discovery of Anti‐CD47 Peptides as Innate Immune Checkpoint Inhibitors
Alicja Urbaniak
University of Arkansas for Medical Sciences
4 shared publications
In database
- Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer
- Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma
- Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response
- Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models
Similar Researchers
Based on overlapping research topics
Mohammad Mamun Alam
University of Arkansas for Medical Sciences
Monoclonal and Polyclonal Antibodies Research
Computational Drug Discovery Methods
SARS-CoV-2 and COVID-19 Research
Behjatolah Monzavi Karbassi
University of Arkansas for Medical Sciences
Cancer Immunotherapy and Biomarkers
Monoclonal and Polyclonal Antibodies Research
Immune Response and Inflammation
Behjatolah Monzavi‐Karbassi
University of Arkansas for Medical Sciences
Cancer Immunotherapy and Biomarkers
Monoclonal and Polyclonal Antibodies Research
Immune Response and Inflammation
Khandoker Usran Ferdous
University of Arkansas for Medical Sciences
Cancer Immunotherapy and Biomarkers
Immune Response and Inflammation
Neoplasms
Xinyu Li
University of Arkansas at Fayetteville
Cancer Immunotherapy and Biomarkers
SARS-CoV-2 and COVID-19 Research
Immune Response and Inflammation
Andrew Johns
University of Central Arkansas
Cancer Immunotherapy and Biomarkers
Immune Response and Inflammation
Neoplasms